Tumour biology: Tumour-associated inflammation versus antitumor immunity

Anticancer Research

Volumn 29, Issue 11, 2009, Pages 4795-4805

  Müller Hübenthal, Boris ^a   Azemar, Marc ^b   Lorenzen, Dirk ^c   Huber, Michael ^d   Freudenberg, Marina A ^e   Galanos, Chris ^e   Unger, Clemens ^b   Hildenbrand, Bernd ^b  

^a Filderklinik ^*  (Germany)

^b TUMOR BIOLOGY CENTER   (Germany)

^c Institute for Tumour Therapy   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

Author keywords

Antitumor immunity; Inflammation; Review; Tumorigenesis

Indexed keywords

ANTIBIOTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DEXAMETHASONE; GAMMA INTERFERON; IMIQUIMOD; LENALIDOMIDE; PROSTAGLANDIN SYNTHASE INHIBITOR; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADENOMA; ADVANCED CANCER; BACTERIAL INFECTION; BASAL CELL CARCINOMA; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER INVASION; CARCINOGENESIS; CELLULAR IMMUNITY; GENETIC PREDISPOSITION; HUMAN; INFECTION; INFLAMMATION; KIDNEY CARCINOMA; MYELOMA; NATURAL KILLER CELL; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; TH1 CELL; TH2 CELL; THYROID CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

ANIMALS; HUMANS; INFLAMMATION; NEOPLASMS;

EID: 75149114140     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Balkwill F and Mantovani A: Inflammation and cancer: Back to Virchow? Lancet 357: 539-545, 2001.
2. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
3. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
4. Balkwill F, Charles KA and Mantovani A: Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211-217, 2005.
5. Schäfer M and Werner S: Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol 9: 628-638, 2008.
6. Rakoff-Nahoum S and Medzhitov R: Toll-like receptors and cancer. Nat Rev Cancer 9: 57-63, 2009.
7. Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, Vora R, Prabhakar U, Nakada M, Corringham RE, DeWitte M, Sturgeon C, Propper D, Balkwill FR and Smyth JF: A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol 19: 1340-1346, 2008.
8. Apte RN, Krelin Y, Song X, Dotan S, Recih E, Elkabets M, Carmi Y, Dvorkin T, White RM, Gayvoronsky L, Segal S and Voronov E: Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour host interactions. Eur J Cancer 42: 751-759, 2006.
9. Van Waes C: Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 13: 1076-1082, 2007.
10. Aggarwal BB, Vijayalekshmi RV and Sung B: Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 15: 425-430, 2009.
11. Pikarsky E: NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 431: 461-466, 2004.
12. Karin M: Nuclear factor-κB in cancer development and progression. Nature 441: 431-436, 2006.
13. Beutler B: Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430: 257-263, 2004.
14. Takeda K and Akira S: Toll-like receptors in innate immunity. Int Immunol 17: 1-14, 2005.
15. Courtois G and Gilmore TD: Mutations in the NF-kappaB signaling pathway: implications for human disease. Oncogene 25: 6831-6843, 2006.
16. Van Waes C: Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 13: 1076-1082, 2007.
17. Rius J: NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α. Nature 453: 807-811, 2008.
18. Garlanda C, Riva F, Veliz T, Polentarutti N, Pasqualini F, Radaelli E, Sironi M, Nebuloni M, Zorini EO, Scanziani E and Mantovani A: Increased susceptibility to colitis-associated cancer of mice lacking TIR8, an inhibitory member of the interleukin-1 receptor family. Cancer Res 67: 6017-6021, 2007.
19. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C and Darnell JE Jr: STAT3 as an oncogene. Cell 98: 295-303, 1999.
20. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D and Yu H: Regulation of the innate and adaptive immune responses by STAT3 signaling in tumor cells. Nat Med 10: 48-54, 2004.
21. Saccani A, Schioppa T, Porta C, Biswas SK, Nebuloni M, Vago L, Bottazzi B, Colombo MP, Mantovani A and Sica A: P50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 66: 11432-11440, 2006.
22. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verástegui E and Zlotnik A: Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56, 2001.
23. De Falco V, Guarino V, Avilla E, Castellone MD, Salerno P, Salvatore G, Faviana P, Basolo F, Santoro M and Melillo RM: Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. Cancer Res 67: 11821-11829, 2007.
24. Burger JA and Kipps TJ: CXCR4: a key receptor in the crosstalk between tumour cells and their microenvironment. Blood 107: 1761-1761, 2006.
25. Kaifi JT, Yekebas EF, Schurr P, Obonyo D, Wachowiak R, Busch P, Heinecke A, Pantel K and Izbicki JR: Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst 97: 1840-1847, 2005.
26. Salvucci O, Bouchard A, Baccarelli A, Deschênes J, Sauter G, Simon R, Bianchi R and Basik M: The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat 97: 275-283, 2006.
27. Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, Foshag L, Bilchik AJ and Hoon DS: Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. Clin Oncol 23: 2744-2753, 2005.
28. Shields JD, Fleury ME, Yong C, Tomei AA, Randolph GJ and Swartz MA: Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell 11: 526-538, 2007.
29. Kawada K, Hosogi H, Sonoshita M, Sakashita H, Manabe T, Shimahara Y, Sakai Y, Takabayashi A, Oshima M and Taketo MM: Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Ocogene 26: 4679-4688, 2007.
30. Kawada K, Sonoshita M, Sakashita H, Takabayashi A, Yamaoka Y, Manabe T, Inaba K, Minato N, Oshima M and Taketo MM: Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 64: 4010-4017, 2004.
31. Shulby SA, Dolloff NG, Stearns ME, Meucci O and Fatatis A: CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res 64: 4693-4698, 2004.
32. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, Wei K, McMaster BE, Wright K, Howard MC and Schall TJ: A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 203: 2201-2213, 2006.
33. Zipin-Roitman A, Meshel T, Sagi-Assif O, Shalmon B, Avivi C, Pfeffer RM, Witz IP and Ben-Barach A: CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res 67: 3396-3405, 2007.
34. Ghadjar P, Coupland SE, Na K, Noutsias M, Letsch A, Stroux A, Bauer S, Buhr HJ, Thiel E, Scheibenbogen C and Keilholz U. Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. J Clin Oncol 24: 1910-1916, 2006.
35. Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, Gould D, Ayhan A and Balkwill F: The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 67: 585-592, 2007.
36. Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR and Wilson JL: The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res 65: 10355-10362, 2005.
37. Bates RC and Mercurio AM: Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell 14: 1790-1800, 2003.
38. Condeelis J and Pollard JW: Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell 124: 263-266, 2006.
39. Robinson-Smith TM, Isaacsohn I, Mercer CA, Zhou M, Van Rooijen N, Husseinzadeh N, McFarland-Mancini MM and Drew AF: Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res 67: 5708-5716, 2007.
40. Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Plüddemann A, Charles K, Gordon S and Balkwill FR: Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol 176: 5023-5032, 2006.
41. Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, Segall JE, Pollard JW and Condeelis J: Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 67: 2649-2656, 2007.
42. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C and Balkwill FR: Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 175: 1197-11205, 2005.
43. Allavena P, Garlanda C, Borrello MG, Sica A and Mantovani A: Pathways connecting inflammation and cancer. Curr Opin Genet Dev 18: 3-10, 2008.
44. Borrello MG, Alberti L, Fischer A, Degl'innocenti D, Ferrario C, Gariboldi M, Marchesi F, Allavena P, Greco A, Collini P, Pilotti S, Cassinelli G, Bressan P, Fugazzola L, Mantovani A and Pierotti MA: Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci USA 102: 14825-14830, 2005.
45. Runeberg-Roos P and Saarma M: Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases. Ann Med 39: 572-580, 2007.
46. Guerra C, Schuhmacher AJ, Cañamero M, Grippo PJ, Verdaguer L, Pérez-Gallego L, Dubus P, Sandgren EP and Barbacid M: Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11: 291-302, 2007.
47. Sparmann A and Bar-Sagi D: Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6: 447-458, 2004.
48. Shchors K, Shchors E, Rostker F, Lawlor ER, Brown-Swigart L and Evan GI: The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. Genes Dev 20: 2527-2538, 2006.
49. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB and Evan GI: Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 13: 1211-1218, 2007.
50. Burstein E and Fearon ER: Colitis and cancer: a tale of inflammatory cells and their cytokines. J Clin Invest 118: 464-467, 2008.
51. Moss SF and Malfertheiner P: Helicobacter and gastric malignancies. Helicobacter 12: 23-30, 2007.
52. Prinz C, Schwendy S and Voland P: H. pylori and gastric cancer: shifting the global burden. World J Gastroenterol 12: 5458-5464, 2006.
53. Oshima H, Oshima M, Inaba K, Taketo MM. Hyperplastic gastric tumors induced by activated macrophages in Cox-2/mPGES-1 transgenic mice. EMBO J 23: 1669-1678, 2004.
54. Ogura K, Hirata Y, Yanai A, Shibata W, Ohmae T, Mitsuno Y, Maeda S, Watabe H, Yamaji Y, Okamoto M, Yoshida H, Kawabe T and Omata M: The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. J Clin Gastroenterol 42: 279-283, 2008.
55. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S and Asaka M: Japan Gast Study Group: Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 372: 392-397, 2008.
56. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB and Hawk ET: APC Study Investigators: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355: 873-884, 2006.
57. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK and Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952, 2000.
58. Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, Cai X, Fox JG, Goldenring JR and Wang TC: Gastric cancer originating from bone marrow-derived cells. Science 306: 1568-1571, 2004.
59. Bosch X: Bone-marrow-derive cells implicated in gastric cancer. Lancet Oncol 6: 8, 2005.
60. Maitland NJ and Collins AT: Inflammation as the primary aetiological agent of human prostate cancer: a stem cell connection? J Cell Biochem 105: 931-939, 2008.
61. Man YG and Gardner WA: Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion. Med Hypotheses 70: 387-408, 2008.
62. Marrache F, Pendyala S, Bhagat G, Betz KS, Song Z and Wang TC: Role of bone marrow-derived cells in experimental chronic pancreatitis. Gut 57: 1113-1120, 2008.
63. Michaud DS: Chronic inflammation and bladder cancer. Urol Oncol 25: 260-268, 2007.
64. Drucker C, Parzefall W, Teufelhofer O, Grasch M, Ellinger A, Schulte-Hermann R and Grasl-Kraupp B: Non-parenchymal liver cells support the growth advantage in the first stages of hepatocarcinogenesis. Carcinogenesis 27: 152-161, 2006.
65. Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, Fogel M, Huszar M, Iwakura Y, Segal S, Dinarello CA and Apte RN: Interleukin-1 beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumours. Cancer Res 67: 1062-1071, 2007.
66. Peinado H, Rafii S and Lyden D: Inflammation joins the niche. Cancer Cell 14: 347-349, 2008.
67. Mantovani A: Cancer: Inflaming metastasis. Nature 457: 36-37, 2009.
68. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL and Karin M: Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457: 102-106, 2009.
69. De Visser KE, Eichten A and Coussens LM: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6: 24-37, 2006.
70. Yao M, Zhou W, Sangha S, Albert A, Chang AJ, Liu TC and Wolfe MM: Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res 11: 1618-1628, 2005.
71. Koehne CH and Dubois RN: COX-2 inhibition and colorectal cancer. Semin Oncol 31: 12-21, 2004.
72. Flossmann E and Rothwell PM: British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369: 1603-1613, 2007.
73. Chan AT, Ogino S and Fuchs CS: Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356: 2131-2142, 2007.
74. Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F and Ganesan TS: Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J Clin Oncol 23: 5950-5959, 2005.
75. Madhusudan S, Foster M, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, Talbot DC, Ganesan TS and Harris AL: A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res 10: 6528-6534, 2004.
76. Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, Vora R, Prabhakar U, Nakada M, Corringham RE, DeWitte M, Sturgeon C, Propper D, Balkwill FR and Smyth JF: A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol 19: 1340-1346, 2008.
77. Harrison ML, Obermueller E, Maisey NR, Hoare S, Edmonds K, Li NF, Chao D, Hall K, Lee C, Timotheadou E, Charles K, Ahern R, King DM, Eisen T, Corringham R, DeWitte M, Balkwill F and Gore M: Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 25: 4542-4549, 2007.
78. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB and Knight RD: Multiple Myeloma (009) Study Investigators: Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357: 2133-2142, 2007.
79. Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD and Weber DM: Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 112: 4445-4451, 2008.
80. Mantovani A, Bottazzi B, Colotta F, Sozzani S and Ruco L: The origin and function of tumor-associated macrophages. Immunol Today 13: 265-270, 1992.
81. Walzer T, Dalod M, Robbins SH, Zitvogel L and Vivier E: Natural-killer cells and dendritic cells: l'union fait la force. Blood 106: 2252-2258, 2005.
82. Yu P and Fu XY: Tumor-infiltrating T lymphocytes: friends or foes? Laboratory Investigation 86: 231-245, 2006.
83. Kalesnikoff J and Galli SJ: New developments in mast cell biology. Nat Immunol 9: 1215-1223, 2008.
84. Bunt SK, Yang L, Sinha P, Clements VK, Leips J and Ostrand-Rosenberg S: Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 67: 10019-10026, 2007.
85. De Palma M, Murdoch C, Venneri MA, Naldini L and Lewis CE: Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol 28: 519-524, 2007.
86. Mantovani A, Sozzani S, Locati M, Allavena P and Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555, 2002.
87. Sica A and Bronte V: Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117: 1155-1166, 2007.
88. + T cells to tumour antigens by dendritic cells leads to enhanced functional avidity and direct tumour recognition through an IL-12 dependent mechanism. J Immunol 171: 2251-2261, 2003.
89. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C and Bhardwaj N: Antigen-specific inhibition of effector T-cell function in humans after injection of immature dendritic cells. J Exp Med 193: 233-238, 2001.
90. Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Plüddemann A, Charles K, Gordon S and Balkwill FR: Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol 176: 5023-5032, 2006.
91. Salgame P: Host innate and Th1 responses and the bacterial factors that control Mycobacterium tuberculosis infection. Curr Opin Immunol 17: 374-380, 2005.
92. Nylén S and Sacks D: Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol 28: 378-384, 2007.
93. Banchereau J and Steinman RM: Dendritic cells and the control of immunity. Nature 392: 245-252, 1998.
94. Schroder K, Hertzog PJ, Ravasi T and Hume DA: Interferon-γ: an overview of signals, mechanisms and functions. J Leukocyte Biology 75: 163-189, 2004.
95. Liakou CI, Narayanan S, Ng Tang D, Logothetis CJ and Sharma P: Focus on TILs: Prognostic significance of tumor-infiltrating lymphocytes in human bladder cancer. Cancer Immun 7: 10, 2007.
96. Ohtani H: Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun 7: 4, 2007.
97. Dunn GP, Dunn IF and Curry WT: Focus on TILs: Prognostic significance of tumor-infiltrating lymphocytes in human glioma. Cancer Immunity 7: 12, 2007
98. +/regulatory T-cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102: 18538-18543, 2005.
99. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Page's C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Braneval P, Cugnenc PH, Trajanoski Z, Fridman WH and Page's F: Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome. Science 313: 1960-1964, 2006.
100. Coley WB: The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci 105: 487-511, 1893.
101. Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, Muranski P, Sanchez-Perez L, Palmer DC, Yu Z, PA A, Gattinoni L, Rosenberg SA and Restifo NP: Toll-like receptors in tumour immunotherapy. Clin Cancer Res 15: 5280-5289, 2007.
102. Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD and Smyth MJ: Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci USA 105: 652-656, 2008.
103. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT and Storkus WJ: Therapy of murine tumours with tumour peptide-pulsed dendritic cells: dependence on T-cells, B7 co-stimulation, and T-helper cell 1-associated cytokines. J Exp Med 183: 87-97, 1996.
104. Brandau S and Suttmann H: Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother 61: 299-305, 2007.
105. Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrándiz C, Garcia Diez A, Tebbs V and McRae S: Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 152: 939-947, 2005.
106. Martin-Garcia RF: New insights into imiquimods mechanisms of action. J Drugs Dermatol 3: 247-249, 2004.
107. Zobywalski A, Javorovic M, Frankenberger B, Pohla H, Kremmer E, Bigalke I and Schendel DJ: Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J Transl Med 12: 5-18, 2007.
108. Fejer G, Drechsel L, Liese J, Schleichert U, Ruzsics Z, Imelli N, Greber U, Keck S, Hildenbrand B, Krug A, Bogdan C and Freudenberg MA: Key role of splenic myeloid DCs in the IFN-αβ response to adenovirus in vivo. Pathogens 11: 1-12, 2008.
109. H1-polarisation of human monocyte-derived dendritic cells matured under serum-free conditions with novel highly purified TLR4-agonists. Onkologie 31: 148, 2008.
110. Hildenbrand B, Sauer B, Kalis O, Stoll C, Freudenberg MA, Niedermann G, Giesler JM, Jüttner E, Peters JH, Häring B, Leo R, Unger C and Azemar M: Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells -A pilot study. Prostate 67: 500-508, 2007.
111. H1-polarisation of monocyte-derived dendritic cells matured with clinical-grade cytokines using serum-free conditions. Anticancer Res 28: 1467-1476, 2008.